• DNA Damage Pathways Modulate Calicheamicin ADC Sensitivity i

  2026-05-26

  This study uses genome-wide CRISPR screening to identify DNA damage sensing and TP53 pathway genes as key modulators of sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) in acute leukemia. The findings delineate actionable targets for combination therapies and highlight the specificity of DNA repair pathway involvement in drug response.

• Lactate-GPR81/FARP1 Axis Enables Insulin-Independent Glucose

  2026-05-26

  This study reveals that lactate stimulates the GPR81/FARP1 signaling axis to enhance glucose uptake independently of insulin via RAC1-driven GLUT4 translocation. These findings provide a mechanistic basis for insulin-independent metabolic control, with implications for diabetes research and therapeutic strategies targeting GPCR signaling.

• BML-277 and the CHK2-cGAS Axis: Rewiring DNA Damage Research

  2026-05-25

  This thought-leadership article examines BML-277, a potent and selective Chk2 inhibitor, as a transformative tool for translational research in DNA damage response, with a focus on the nuclear CHK2-cGAS-TRIM41-ORF2p axis. Integrating mechanistic insights from recent high-impact studies, the article provides strategic guidance for researchers working at the intersection of genome stability, radioprotection, and cancer biology, highlighting protocols, competitive context, and future outlook.

• Cholesterol Impedes Lipid Nanoparticle Trafficking in Cells

  2026-05-25

  This study reveals that increased cholesterol content in lipid nanoparticles (LNPs) hinders their intracellular trafficking by promoting aggregation in peripheral early endosomes, ultimately reducing nucleic acid delivery efficiency. The findings clarify the distinct roles of LNP components in endosomal escape and provide new mechanistic insights for optimizing nonviral gene delivery systems.

• Balsalazide Disodium: Advances in Ulcerative Colitis Managem

  2026-05-24

  The reference study by Wiggins & Rajapakse systematically reviews Balsalazide disodium as an innovative 5-aminosalicylate prodrug for ulcerative colitis. Its targeted colonic activation and favorable remission profile mark a significant advance in the treatment of mild-to-moderate UC, with implications for both clinical research and mechanistic inflammation studies.

• Harnessing MEK Inhibition: PD0325901 in Translational Oncolo

  2026-05-23

  This article examines the mechanistic foundation and translational impact of PD0325901, a potent and selective MEK inhibitor. By integrating recent advances in RAS/RAF/MEK/ERK pathway research and cross-linking findings from pluripotency and cancer biology, we offer actionable guidance for researchers advancing targeted therapeutic strategies. With context from the Trim71-let-7 axis and contemporary validation studies, we position PD0325901 as a cornerstone for both pathway dissection and preclinical tumor suppression.

• Honokiol as a Precision Tool for In Vitro NF-κB Pathway Diss

  2026-05-22

  Explore Honokiol’s unique role as a selective NF-κB pathway inhibitor and antioxidant in advanced in vitro research. This deep-dive links molecular mechanisms to assay design decisions, offering new guidance beyond standard cancer and inflammation workflows.

• QNZ (EVP4593): Redefining NF-κB Modulation in Bone Infection

  2026-05-22

  This thought-leadership article explores the pivotal role of QNZ (EVP4593) as a next-generation NF-κB pathway inhibitor, illuminating its mechanistic advantages and translational potential in both inflammatory bone infections and neurodegenerative disease models. Drawing on breakthrough findings from osteomyelitis research and advanced workflow resources, the piece guides translational scientists in leveraging QNZ (EVP4593) for robust, reproducible insights that bridge molecular biology with clinical innovation.

• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-05-21

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) is a water-soluble carbodiimide reagent designed for efficient amide bond formation in peptide synthesis, bioconjugation, and nucleotide coupling. It is strictly intended for in vitro protocols and should not be used in in vivo or clinical settings due to the absence of supporting data.

• Spatially Concentrated Base Editors Correct PLP1 Mutations i

  2026-05-21

  This study presents a spatially concentrated adenine base editor (cABE) that achieves efficient and precise correction of PLP1 mutations in oligodendrocytes, a key advance for treating Pelizaeus–Merzbacher disease. The findings reveal that spatial reorganization, rather than catalytic enhancement, drives robust editing in difficult-to-modify cell types.

• Sulfo-NHS-Biotin: Advanced Protein Labeling for Cell Profili

  2026-05-20

  Sulfo-NHS-Biotin empowers researchers to achieve high-fidelity, water-soluble protein labeling with unmatched selectivity for cell surface applications. Its membrane-impermeant chemistry and proven compatibility with high-throughput functional assays set a new gold standard for single-cell and proteomic workflows.

• Dual Recombinase Tracing Refutes Postnatal Neo-oogenesis in

  2026-05-20

  Xie et al. employed a dual recombinase genetic tracing strategy to rigorously test whether new oocytes are generated after birth in mice. Their results demonstrate that, even after chemically induced germ cell depletion, adult female mice do not exhibit in vivo neo-oogenesis, refining our understanding of ovarian biology and experimental modeling.

• GPNMB-Driven Model Predicts Immunotherapy Response in ESCC

  2026-05-19

  This study introduces a multimodal model that integrates circulating GPNMB levels and tumor microenvironment features to accurately predict immunotherapy response in esophageal squamous cell carcinoma (ESCC). The findings elucidate the mechanism of CD8+ T cell exhaustion and provide a clinically scalable framework for precision patient stratification.

• EZ Cap EGFP mRNA 5-moUTP: Workflow Optimization and Imaging

  2026-05-19

  EZ Cap™ EGFP mRNA (5-moUTP) delivers robust, reproducible enhanced green fluorescent protein mRNA expression, uniquely combining Cap 1 capping and 5-moUTP modification for minimized immunogenicity. This article explores practical workflows, advanced imaging use-cases, and actionable troubleshooting rooted in the latest evidence.

• Actinomycin D in Neurodegeneration: Beyond Cancer Research

  2026-05-18

  Explore the advanced role of Actinomycin D in probing transcriptional stress and DNA damage response in neurodegenerative disease models. This in-depth analysis reveals unique scientific insights and protocol nuances for leveraging ActD in oligodendrocyte and Parkinson’s research.

3717 records 16/248 page Previous Next First page 上5页 1617181920 下5页 Last page